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Abstract The phagocyte NADPH oxidase is activated during 
phagocytusis to produce superoxide, following assembly of a 
membrane-integrated cytochrome b5~ with cytosolic proteins, 
p47 eh°x, p67 ph°x and p40 eh°x, each containing Src homology 3 
(SH3) domains. While both p47 rh°x and p67 ph°/are indispensable 
for the oxidase activity, role of p40 ~°x remains obscure. Here we 
study interaction between p40 ph°~ and p47 ph°~ by two independent 
methods, a two-hybrid system in the yeast and an in vitro binding 
assay using purified proteins. The present results show that the 
interaction is mediated via binding of the SH3 domain of p40 ph°x 
to a C-terminal proline-rich region of p47 eh°x. This profine-rich 
region is also the target for binding of p67 ph°/, and the SH3 
domain of p40 eh°x can inhibit the binding of the C-terminal one of 
p67 p~t°x to p47 ph°~. 
Key words: NADPH oxidase; SH3 domain; Proline-rich 
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1. Introduction 
The phagocyte NADPH oxidase is dormant in resting cells, 
and activated uring phagocytosis to catalyze the one-electron 
reduction of molecular oxygen in conjunction with oxidation 
of NADPH to generate superoxide (O2-), a precursor of mi- 
crobicidal oxidants [1,2]. The importance of the oxidase to 
host immunity is evident from that recurrent severe infection 
occurs in patients with chronic granulomatous disease (CGD) 
whose phagocytes are deficient in superoxide production [3]. 
Activation of the NADPH oxidase involves assembly of 
cytochrome bs~s, a membrane-integrated flavocytochrome 
comprising gp91 ph°x and p22 ph°~, with cytosolic proteins 
such as p47 oh°z, p67 ph°x and the small G-protein Rac (Racl 
and/or Rac2) [1,2]. The factors that reside in the cytosol of 
resting cells, upon activation translocate to the membrane to 
form a complex with cytochrome bsas [1,2]. The translocation 
of p47 ph°x and p67 ph°x requires interaction between p47 ph°x 
and cytochrome b55s; p47 °h°x carries p67 ph°~ into an active 
oxidase complex where the cytochrome provides a docking 
site [4,5]. 
Both p47 ph°x and p67 ph°x contain two Src homology 3 
(SH3) domains. The domain is present in many signaling pro- 
teins and known to mediate interactions via binding to pro- 
**Corresponding author. Fax: (81) (3) 5449-5445. 
**Corresponding author. Fax: (81) (92) 632-2373. 
Abbreviations: CGD, chronic granulomatous disease; SH3, Src 
homology 3; GST, glutathione S-transferase; MBP, maltose binding 
protein 
line-rich regions in target proteins [6,7]. Current evidence in- 
dicates that SH3 domains function in assembly of the 
NADPH oxidase factors [8-11]. An SH3 domain of p47 ph°~ 
appears to be critical for interaction with cytochrome bs~s; it 
binds to the C-terminal cytoplasmic domain of p22 ph°x but 
fails to interact with a mutant p22 ph°z carrying Prol~6Gln 
substitution in a proline-rich region, which is found in a pa- 
tient with CGD [8,10]. On the other hand, the C-terminal SH3 
domain of p67 ph°z is involved in binding to p47 ph°x [9-11]. 
The protein p40 ph°x containing an SH3 domain was origin- 
ally identified as one that tightly associates with p67 ph°~ in 
resting phagocytes [12-14], but its role is poorly understood. 
Although p40 ph°x as well as p47 ph°~ and p67 ph°x seems to 
translocate to the membrane upon cell stimulation depending 
on the presence of cytochrome bs~s [13], the NADPH oxidase 
activity can be reconstituted without p40 vh°x under cell-free 
activation conditions [15,16], suggesting that p40 ph°x may play 
a role in modulation of the activity. A recent study using the 
yeast two-hybrid system has shown that the C-terminal por- 
tion of p40 ph°z but not its SH3 domain is involved in associa- 
tion with p67Phox, and that a region containing the SH3 do- 
main of p40 ph°x can interact with p47 ph°x [17]. Little is, 
however, known about interaction between p40 ph°x and 
p47 ph°z, including the question which site of p47 ph°z is respon- 
sible for the binding to p40 ph°x. 
As a step for understanding the role of p40 ph°x, we focused 
on interaction between p40 ph°x and p47 ph°x, since p47 ph°z 
seems to play a central role in assembly of the NADPH oxi- 
dase factors. The present results obtained by two independent 
methods, the two-hybrid system and an in vitro binding assay 
using expressed proteins, indicate that the interaction is 
mediated via binding of the SH3 domain of p40 ph°x to a C- 
terminal proline-rich region of p47 ph°z, a region which is also 
the target for the p67 ph°× binding. 
2. Materials and methods 
2.1. Two-hybrid experiments 
The vectors and strains used for two-hybrid experiments were ob- 
tained from Clontech Lab., Inc. (CA, USA). The multiple cloning 
sites of pGAD424 and pGBT9 were modified so that the inserts 
from glutathione S-transferase (GST) fusion plasmids (pGEX-2T, 
Pharmacia Biotech) can be readily transferred in correct orientation 
and reading frames. Human cDNAs encoding the N-terminal (amino 
acid residues 1-167), SH3 (amino acid residues 168-233) and C-term- 
inal domains (amino acid residues 234-339) of p40 ph°~ were amplified 
from differentiated HL60 RNAs by RT-PCR and cloned into the 
BamHI and EcoRI sites of the modified GAL4 activation domain 
vector, pGAD424g. The obtained plasmids were named 
pGAD::p40-N, pGAD::p40-SH3 and pGAD::p40-C, respectively. 
A mutant p40-SH3 carrying Trp2°7Arg substitution was made by 
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Fig. 1. Interaction of p40 ;h°x with p47 vh°x analyzed by the yeast 
two-hybrid system. The yeast strain HF7c was cotransformed with 
pairs of recombinant plasmids pGAD424 and pGBT9, the former 
encoding the indicated omain of p40 ph°~ fused to the GAL4 activa- 
tion domain and the latter encoding the indicated domain of 
p47 ph°~ fused to the GAL4 DNA-binding domain. All the possible 
pGAD424 and pGBT9 plasmid pairs were tested for the His + phe- 
notype. The structure of domains and intact proteins is schemati- 
cally illustrated. Shaded boxes indicates SH3 domains. (vector) indi- 
cates the cloning vector used as a negative control. 
PCR-directed mutagenesis and ligated to pGAD424g to yield 
pGAD :: p40-SH3(W207R). Human cDNAs encoding N-terminal 
(amino acid residues 1-153), SH3(N) (amino acid residues 154-219), 
SH3(C) (amino acid residues 223-286), and C-terminal domains (ami- 
no acid residues 286-390) of p47 ph°z were transferred from corre- 
sponding GST-fusion constructs [8] to the modified GAL4 DNA- 
binding domain vector, pGBT9g, thereby constructing pGBT: :p47- 
N, pGBT:: p47-SH3(N), pGBT :: p47-SH3(C) and pGBT :: p47-C, re- 
spectively. Deletion mutants of pGAD::p47-C, namely p47-CAP1, 
p47-CAP2 and p47-CAP1P2, were lacking amino acid residues 299- 
346, 360-390, and 341-368, respectively. The domains of p47 oh°x, N- 
terminal (amino acid residues 1-153), (SH3)2 (amino acid residues 
154-286) and C-terminal domains (amino acid residues 28(~390), 
were also transferred from corresponding GST-fusion constructs [8] 
to pGAD424g, constructing pGAD :: p47-N, pGAD :: p47-(SH3)2 and 
pGAD:: p47-C, respectively. Similarly, from the corresponding inserts 
of pGEX-2T (H.S., unpublished), four plasmids for human p67 ph°x 
were constructed, namely pGBT:: p67-N (amino acid residues 1-232), 
pGBT::p67-SH3(N) (amino acid residues 228-291), pGBT::p67-1S 
(amino acid residues 291~,50) and pGBT::p67-SH3(C) (amino acid 
residues 445-516). The C-terminal SH3 domain of p67 ph°z was also 
ligated to pGAD424g, constructing pGAD::p67-SH3(C). These plas- 
mids were used following the confirmative DNA sequencing. 
All the possible pairs between the pGAD and pGBT plasmids were 
cotransformed into competent yeast HF7c cells with HIS3 and lacZ 
reporter genes using a modified lithium-acetate method [18]. Follow- 
ing the selection for Leu + and Trp + phenotype, transformants were 
tested for their ability to grow on plates lacking histidine. These in- 
dicator plates were supplemented with 10 mM 3-aminotriazole to 
suppress the background growth due to leaky expression of HIS3 
gene in HF7c cells. Activation of laeZ reporter was examined by 
the filter assay according to the manufacturer's ecommendation. 
For the competitive two-hybrid assay, cDNA encoding the C-term- 
inal SH3 domain of p67 vh°x was cloned into a newly constructed 
activation domain vector pGAF (T.I., unpublished), a derivative of 
pGAD424g carrying URA3, instead of LEU2, as the selection marker, 
to obtain pGAF :: p67-SH3(C). To express the SH3 domain of p40 ph°x 
as the competitor, its cDNA fragment was cloned into the MluI site, 
but not the conventional c oning sites, of pACT2, a high-expression 
type activation domain vector (Clontech Lab., Inc., CA, USA), to 
obtain pACTA::p40-SH3. This construct directs the expression of 
the SH3 domain fused to an intact nuclear localization signal and a 
part of the GAL4 activation domain, which shows no transcription 
activation. The plasmids pGBT::p47-CAP1 and pGAF::p67-SH3(C) 
were cotransformed with pACT2 or pACTA::p40-SH3 into Y187z 
strain (T.I., unpublished), a ura3 derivative of Y187. Following the 
selection of triple transformants for Trp +, Ura + and Leu + phenotype, 
the activation of lacZ reporter was examined by the filter method. 
2.2. In vitro binding assay using purified proteins 
The maltose binding protein (MBP) fusion expression vector 
pMAL-c2 (New England BioLab, MA, USA) was also modified in 
its multiple cloning site to facilitate the transfer of inserts from 
pGEX-2T plasmids. The modified vector, pMAL-c2g, was used for 
the expression of the three regions of p40 ph°x. Expressed proteins were 
purified using amylose resin (New England BioLab, MA, USA). The 
individual domains of p47 ph°z were expressed as GST fusion proteins 
and purified using glutathione Sepharose beads (Pharmacia Biotech) 
as described previously [8]. The purified GST fusion proteins were 
subjected to 9% SDS-polyacrylamide g l electrophoresis and trans- 
ferred to nitrocellulose membrane. Following the blocking with non- 
fat dry milk, the filters were incubated with MBP fusion proteins and 
washed as described previously [8]. Then, the washed filters were 
probed with anti-MBP antibody (New England BioLab, MA, USA), 
and the complex was detected using secondary anti-mouse IgG anti- 
bodies conjugated with peroxidase (Sigma) and a POD immunostain 
kit (Wako, Osaka, Japan) according to the manufacturer's instruc- 
tions. 
3. Results and discussion 
In the present study on interaction between p40 ph°z and 
p47 ph°~, we first used a two-hybrid system in the yeast. Fuchs 
et al., using the system, have recently shown that the region 
containing the SH3 domain of p40 ph°x and its adjacent regions 
(amino acids 146-260) is involved in interaction with p47 ph°x, 
leaving the target on the latter unclear [17]. To clarify whether 
the interaction requires the SH3 domain itself or its adjacent 
regions, we prepared a construct comprising solely the SH3 
12345 
Fig. 2. In vitro interaction between p40 ph°x and p47 ph°x. The four 
domains of p47 ph°x expressed as GST fusion proteins and GST were 
subjected to SDS-PAGE, and transferred to a nitrocellulose filter: 
GST-p47-N (lane 1), GST-p47-SH3(N) (lane 2), GST-p47-SH3(C) 
(lane 3), GST-p47-C (lane 4) and GST (lane 5). The filter was sub- 
sequently overlaid with the SH3 domain of p40 ph°x fused to MBP 
as a probe. 
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Fig. 3. Mapping of the p40 ph°~ SH3 domain binding site on p47 ph°z. 
The vector pGAD424 encoding wild-type SH3 domain of p40 ph°~ 
(wt) or its mutant carrying the Trp2°TArg substitution (mt) was co- 
transformed into yeast strain HF7c with the vector pGBT9 encod- 
ing the C-terminal portion of p47 ph°x (tM7-C) or its deletion mutants 
(p47-CAP1, p47-CAP2, or p47-CAP1P2). All the possible pGAD424 
and pGBT9 plasmid pairs were tested for the His + phenotype. The 
structure of p47-C and its derived proteins is schematically illu- 
strated. Proline-rich regions are indicated by shaded boxes. 
domain of p40 ph°x (amino acids 168-233) as well as those of 
the N-terminal and C-terminal domains, and fused them to 
the activation domain of GAL4 on the vector pGAD424g to 
obtain pGAD :: p40-SH3, pGAD :: p40-N and pGAD :: p40-C, 
respectively. On the other hand, for mapping the responsible 
region of p47 ph°x, the protein was divided into N-terminal, the 
N-terminal SH3, the C-terminal SH3 and C-terminal do- 
mains, each of which was fused to the DNA-binding domain 
of GAL4 on the pGBT9g vector to construct pGBT:: p47-N, 
pGBT :: p47-SH3(N), pGBT :: p47-SH3(C) and pGBT :: p47-C, 
respectively. All the possible pairs between the pGAD: :p40 
and pGBT::p47 plasmids were introduced into competent 
HF7c cells and tested for activation of HIS3 reporter gene. 
As shown in Fig. 1, the strain bearing both pGAD::p40-SH3 
and pGBT::p47-C, but not other combinations, grew on the 
plate lacking histidine. The activation of lacZ reporter was 
confirmed by the filter assay (data not shown). These results 
indicate that the SH3 domain of p40 ph°z mediates interaction 
with p47 ph°z via binding to the C-terminal portion. 
To confirm that the SH3 domain of p40 ph°x directly inter- 
acts with the C-terminal portion of p47 ph°x, we expressed and 
purified all the domains of both proteins, and used them for 
an in vitro binding assay: the four domains of p47 ph°z fused 
to GST were transferred to membrane and probed with the 
three domains of p40 ph°z tagged with MBP. When the SH3 
domain of p40 ph°x was used as a probe, a positive interaction 
was detected only with the C-terminal portion of p47 ph°~: (Fig. 
2), On the other hand, the other two domains of p40 ph°z did 
not interact with any portions of p47 ph°x (data not shown). 
These results were in complete agreement with the two-hybrid 
data described above, and we thus conclude that direct bind- 
ing of the SH3 domain of p40 ph°x to the C-terminal portion of 
p47 ph°z mediates interaction between these two proteins, but 
other domains or portions are not involved in the interaction. 
To further investigate the nature of the interaction, we in- 
troduced a mutation into the SH3 domain of p40 ph°x, causing 
replacement of Trp-207 by Arg. This tryptophan residue is the 
most conserved one in SH3 domains [19], and it directly inter- 
acts with a proline of target peptides [20,21]. The equivalent 
mutations ( ubstitution of Arg or Leu for Trp) in Src and Crk 
result in loss of function [22,23]. The mutant p40 ph°~ SH3 
domain carrying the Trp2°TArg substitution failed to interact 
with the C-terminal portion of p47 ph°x (Fig. 3), indicating that 
the interaction occurs in a manner common to those via SH3 
domains. As is well established, targets of SH3 domains are 
proline-rich regions and the minimal requirement is a Pro-Xa- 
Xa-Pro motif [20]. In the C-terminal portion of p47Phox, the 
motif exists in stretches of Proa41-Gly-Pro-Gln-Ser-Pro-Gly - 
Ser-Pro 34~ and Pro361-Gln-Pro-Ala-Val-Pro-Pro-Arg-Pro360. 
To determine which is involved in interaction with the SH3 
domain of p40 ph°z, we made three constructs: a p47-C lacking 
the former stretch (p47-CAP1); without he latter (p47-CAP2); 
deleting both (p47-CAP1P2). Two-hybrid assays were per- 
formed using these constructs (Fig. 3). All of the p47 oh°x fu- 
sion proteins that interacted with the SH3 domain of p40 ph°x 
shared a common proline-rich stretch of Pro361-Gln-Pro-Ala- 
Val-Pro-Pro-Arg-Pro 369, indicating that the SH3 domain of 
p40 ph°z binds the C-terminal proline-rich region of p47 ph°x. 
The C-terminal portion of p47 ph°z seems to be not only the 
target of p40 ph°x but also that of p67 ph°x. Binding assays in 
vitro have shown that the C-terminal SH3 domain of p67 ph°x 
interacts with this portion of p47 ph°z [9,10]. To verify that the 
interaction occurs in vivo, we carried out two-hybrid experi- 
ments. The DNA-binding domain of GAL4 on the pGBT9g 
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p67-SH3(N) [ ]  
p67-1S I I 
p67-SH3(C) [ ]  
B p67-SH3(C) 
p47-C 
p47-CAP1 
p47-CAP2 
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Fig. 4. Interaction of p67 ph°~ with p47;h°L (A) The four domains of 
p67 ph°x expressed as fusion with the GAL4 DNA-binding domain 
were tested for interaction with the three portions of p47 ph°z fused 
to the GAL4 activation domain, in yeast HF7c cells. (B) Various 
deletion mutants of the p47 ph°z C-terminal portion (p47-C), as fu- 
sion with GAL4 DNA-binding domain, were tested for interaction 
with the C-terminal SH3 domain of p67 ph°z (p67-SH3(C)) fused to 
the GAL4 activation domain, in yeast HF7c cells. Interactions be- 
tween proteins are demonstrated by histidine-independent growth. 
The structure of domains and intact proteins is schematically i lu- 
strated. Shaded boxes indicate SH3 domains (A) or proline-rich re- 
gions (B). (vector) indicates the cloning vector used as a negative 
control. 
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pGAF pACT~-p40-SH3 
pGAF::p67oSH3(C) pACT2 
pGAF::p67-SH3(C) pACTA-p40-SH3 
Fig. 5. In vivo inhibition of p67 ph°x binding to p47 ph°z by the SH3 
domain of p40 ph°z. The plasmids pGBT:: p47-CAPI and 
pGAF::p67-SH3(C) (or pGAF) were cotransfomed with pACT2 or 
pACTA::p40-SH3 into Y187z strain, a ura3 derivative of Y187. Fol- 
lowing the selection of triple transformants for Trp +, Ura + and 
Leu + phenotype, the activation of lacZ reporter was examined by 
the filter method. 
vector was fused to the N-terminal portion, the N-terminal 
SH3 domain, the portion between both SH3 domains (inter- 
SH3 portion) and the C-terminal SH3 domain of p67 ph°x to 
obtain pGBT::p67-N, pGBT::p67-SH3(N), pGBT::p67-IS 
and pGBT::p67-SH3(C), respectively. All the possible pairs 
between the pGBT::p67 and pGAD::p47 plasmids were 
tested for activation of the HIS3 reporter gene. Only the 
strain bearing both pGBT::p67-SH3(C) and pGAD::p47-C 
showed the His + phenotype (Fig. 4A). Thus the C-terminal 
SH3 domain of p67 ph°x interacts with the C-terminal portion 
of p47 ph°x in vivo as well as in vitro. We next pinpointed the 
target region on p47 ph°~. As shown in Fig. 4B, strains that 
grew without histidine all expressed both the C-terminal SH3 
domain of p67 ph°~ and, as a part of the fusion protein, a 
proline-rich stretch of Pro361-Gln-Pro-Ala-Val-Pro-Pro-Arg- 
Pro 369 on p47 ph°x. This indicates that the target of p67 ph°x is 
the C-terminal proline-rich region of p47 ph°x, which is consist- 
ent with that determined by in vitro binding assays [9,10]. It 
should be noted that this region was also responsible for bind- 
ing of p40 p~°~ (Fig. 3). 
The finding that the same region on p47 ph°~ is recognized by 
the p40 ph°x SH3 domain and by the C-terminal one of p67 ph°x 
suggests that the two SH3 domains compete with each other 
in binding to p47 ph°x. To test this possibility, we designed an 
in vivo competition assay, in which the effect of the overex- 
pressed SH3 domain of p40 ph°x on the interaction between 
p47 ph°x and p67 pn°x was examined using the yeast wo-hybrid 
system. The interaction between the two was readily detected 
by lacZ reporter activation in the presence of control plasmid 
pACT2, whereas it was severely impaired when the SH3 do- 
main of p40 ph°~ was overexpressed from pACTA::p40-SH3 
(Fig. 5). Thus the SH3 domain of p40 ph°x can inhibit, prob- 
ably by competition, the binding of the C-terminal one of 
p67 ph°x to the proline-rich region of p47 ph°~. 
Interaction between p47 ph°x and p67 ph°x in stimulated pha- 
gocytes is considered to play a crucial role in forming an 
active NADPH oxidase complex, since p47 ph°~ is indispensa- 
ble for translocation of p67 ph°x to the membrane where cyto- 
chrome b558 resides [4]. Our in vivo data (Fig. 4), as well as 
those obtained in vitro [10], suggest hat the interaction is 
solely mediated via binding of the C-terminal SH3 domain 
of p67 ph°x to the C-terminal proline-rich region of p47Ph°L 
The importance of the C-terminal SH3 domain is also sup- 
ported by the finding that p67 ph°x deleting this domain fails to 
restore oxidase activity in Epstein-Barr virus-transformed B 
lymphocytes that lack p67 ph°~ [24]. As shown in this study, 
the p40 ph°x SH3 domain recognizes and binds the same region 
on p47 ph°x as the C-terminal SH3 domain of p67 ph°x does. 
Competition between p40 ph°x and p67 oh°× in binding to 
p47 ph°~ may modulate the NADPH oxidase activity. 
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